EL7.AI
StocksMedium•29 July 2026•
1 min read

The Lancet Publishes Positive Phase 3 Data for Capricor’s Deramiocel

Key Facts

1The Lancet published HOPE-3 data showing Deramiocel slowed upper limb function decline by 54% in Duchenne muscular dystrophy patients.

In a move that strengthens scientific confidence within the biotech sector, Capricor Therapeutics announced that The Lancet has published results from its pivotal Phase 3 HOPE-3 clinical trial. The published data demonstrated that Deramiocel slowed the decline of upper limb function by 54% in patients with Duchenne muscular dystrophy (DMD). According to reports, the publication confirms that the trial met its primary endpoint with statistical significance (p=0.03).

This external peer-reviewed validation follows a period of extreme volatility for the company's stock, which recently experienced a 67% decline despite the positive clinical findings. Per market data, the publication in a top-tier medical journal provides critical third-party verification of the trial design and findings, serving as a landmark milestone for both the medical community and biotech investors navigating high-risk assets.

Looking ahead, investors are focused on the FDA’s decision regarding the Biologics License Application (BLA) for Deramiocel, which has a target action date of August 22, 2026.